020757-5002
Bristol-Myers Squibb
Attention: Douglas B. Hay, Ph.D.
P.O. Box 4000
Princeton, NJ 08543-4000

Dear Dr. Hay:

Please refer to your December 15, 1997 supplemental new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Avapro (irbesartan) 75 mg, 150 mg and 300 mg, Tablets.

The user fee goal date is June 17, 1998.

The supplemental application provides for a new method for the used in the synthesis of drug substance irbesartan.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Sincerely yours,

James H. Short, Ph.D.
Acting Chemistry Team Leader, DNDC I
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
cc: NDA 20-757/ S-002
    HFD-110/ DIV FILE
    HFD-110/ RMittal
    HFD-110/ Project Manager/ KBongiovanni
    HFD-92
    DISTRICT OFFICE
    HFD-810/ CHoiberg
    cg/01/27/98

Approval Date: September 30, 1997

APPROVAL
DIVISION OF CARDIO-RENAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

ND A #: 20-757/SCS-002
SUBMISSION TYPE: SCS-002
DOCUMENT DATE: 15-DEC-97
CDER DATE: 17-DEC-97
ASSIGNED DATE: 18-DEC-97

NAME & ADDRESS OF APPLICANT
Bristol Myers Squibb Company
P. O. Box 4000
Princeton, NJ 08543-4000

SUPPLEMENT PROVIDES FOR:
SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED

DRUG PRODUCT NAME

Established Name: Irbesartan
Proprietary: AVAPRO
Nonproprietary/USAN: Irbesartan
Code Name/#: SR 47,436, BMS-186295, BMS-186295-01
Chem.Type/Ther.Class: 1/3

AND Suitability Petition/DES/I Patent Status:
The U.S. Patent 5,270,317 held by Elf Sanofi was issued for irbesartan and is due to expire on March 2011.

PHARMACOL.CATEGORY/INDICATION: Angiotensin II Receptor Antagonist/Hypertension
DOSAGE FORM: TABLETS
STRENGTH: 75 mg, 150 mg and 300 mg.
ROUTE OF ADMINISTRATION: ORAL
DISPENSED: Rx

CHEMICAL NAME 2-Butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,3-diazaspiro[4.4]non-1-ene-4-one.
CAS #: 138402-11-6
MOLECULAR FORMULA C_{25}H_{34}N_{6}O
MOLECULAR WEIGHT 426.5

STRUCTURAL FORMULA
SUPPORTING DOCUMENTS:
None

RELATED DOCUMENTS (if applicable): NDA 20-758 Irbesartan/Hydrochlorothiazide

CONSULTS: None at present.

REMARKS/COMMENTS:
None

CONCLUSIONS & RECOMMENDATIONS:
Satisfactory and approval letter is being sent.

cc:
HFD-110/Division File
HFD-110/Ram Mittal/date
HFD-110/CSO

R/D Init by: JShort/
James Short
1/22/98

Ramsharan D. Mittal Ph.D., Review Chemist
fileame: C: \NDA\20757\20757S.002